Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Inyección de GT201 para el tratamiento de tumores sólidos avanzados

6 de noviembre de 2026 actualizado por: Grit Biotechnology

Un estudio clínico de fase I/II de un solo grupo de inyección de linfocitos infiltrantes de tumores autólogos (GT201) para el tratamiento de tumores sólidos avanzados

This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

78

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yue He, PhD
  • Número de teléfono: +86- 13501950200
  • Correo electrónico: william5218@126.com

Ubicaciones de estudio

    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510060
        • Reclutamiento
        • Sun Yat-sen University Cancer Center
        • Investigador principal:
          • Zhiming Li, PhD
        • Contacto:
    • Guangxi
      • Nanning, Guangxi, Porcelana, 530021
        • Reclutamiento
        • Guangxi Medical University Cancer Hospital
        • Contacto:
        • Investigador principal:
          • Song Qu, PhD
    • Hunan
      • Changsha, Hunan, Porcelana, 410013
        • Reclutamiento
        • Hunan Cancer Hospital, Xiangya School of Medicine, Central South University
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Yaqian Han, PhD
        • Investigador principal:
          • Yongchang Zhang, PHD
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200080
        • Reclutamiento
        • Shanghai General Hospital
        • Contacto:
        • Investigador principal:
          • Pin Dong, PhD
      • Shanghai, Shanghai Municipality, Porcelana, 200000
        • Reclutamiento
        • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
        • Investigador principal:
          • Yue He, PhD
        • Contacto:
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610000
        • Reclutamiento
        • West China Hospital, Sichuan University
        • Investigador principal:
          • Lei Liu, PhD
        • Contacto:
          • Lei Liu, PhD
          • Número de teléfono: +86 18980606231
          • Correo electrónico: 32498600@qq.com
        • Investigador principal:
          • Li Zheng, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 1. Voluntarily enroll in the study, sign the informed consent form (ICF), and be willing and able to comply with the study protocol.

  • 2. Aged 18 to 70 years old. For subjects older than 70 years old, eligibility shall be jointly determined by the Investigator and the Sponsor's Medical Monitor.

  • 3. Diagnosis:

    • Phase I trial: Patients with advanced solid tumors who have failed standard therapy, have no available standard therapy, or cannot tolerate standard therapy.
    • Phase II trial: Patients with the target indication who have progressed or are intolerant after receiving the specified treatment outlined in the protocol, and who meet the inclusion and exclusion criteria for the target indication.
  • 4. At least one lesion that is resectable for the preparation of autologous TIL cells.

  • 5. At least one measurable lesion that meets the definition of RECIST v1.1 after tumor sampling.

  • 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  • 7. Estimated survival time ≥ 12 weeks.

  • 8. Functions of major organs meet the requirements specified in the protocol.

  • 9. Female or male subjects of childbearing potential who have not undergone surgical sterilization must agree to use at least one medically acceptable contraceptive method (e.g., intrauterine device, oral contraceptives, condoms) during study treatment and for 1 year after the end of study treatment. For female subjects of childbearing potential without surgical sterilization, serum human chorionic gonadotropin (hCG) test must be negative within 7 days prior to cell infusion.

  • 10. Prior treatment related adverse events shall have recovered to Grade ≤ 1 per Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 before tumor sampling, or be judged by the investigator together with the sponsor's medical monitor not to interfere with the study.

  • 11. For participants enrolled in this study due to disease progression, imaging documentation confirming disease progression following the prior therapy must be available before tumor sampling.

Exclusion Criteria:

  • 1. Patients with spinal cord compression not relieved by surgery and/or radiotherapy are excluded. (Patients may be enrolled if clinical evidence confirms symptom relief for ≥ 1 week prior to tumor harvesting.)

  • 2. Participants with uncontrolled tumor related pain as judged by the investigator. Participants requiring analgesic medications must have a stable analgesic regimen at study entry. Symptomatic lesions suitable for palliative radiotherapy should have completed treatment prior to study entry.

  • 3. Bleeding events within 3 months prior to screening.

  • 4. Patients with arterio-venous thrombotic events that occurred within 6 months prior to screening.

  • 5. Respiratory disorders that severely impair pulmonary function at screening.

  • 6. History of clinically significant cardiovascular disease, including but not limited to:

    1. Congestive heart failure (New York Heart Association [NYHA] Class >grade II);
    2. Unstable angina pectoris;
    3. Myocardial infarction within the previous 3 months;
    4. Any supraventricular or ventricular arrhythmia requiring treatment or intervention.
  • 7. Participants with ≥ 3 untreated central nervous system (CNS) metastases.

  • 8. Any active autoimmune disease, history of autoimmune disease, or diseases requiring systemic corticosteroids (>10 mg prednisone daily or equivalent) or immunosuppressive agents.

  • 9. Malignant tumors other than the target indication within 5 years.

  • 10. Presence of intractable epilepsy, medically uncontrolled pleural effusion, ascites, pericardial effusion, or any contraindication to IL-2 administration.

  • 11. Active infectious diseases within 1 year prior to screening, such as HIV infection, syphilis, active hepatitis, active pulmonary tuberculosis, active Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV) infection; OR history of active pulmonary tuberculosis infection more than 1 year ago without standard treatment; active hepatitis B or hepatitis C.

    • Participants positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) may enroll if HBV DNA level is below the lower limit of quantification (LLOQ) of the local study laboratory.
    • Participants positive for HCV antibody may enroll if HCV RNA level is below the LLOQ of the local study laboratory.
    • Participants with EBV DNA above the laboratory LLOQ may enroll if the Investigator assesses the viremia is tumor-related and the infection is non-active.
    • Carriers enrolled in the study shall receive antiviral therapy at the Investigator's discretion, with regular quantitative nucleic acid testing scheduled throughout the study period.
  • 12. Use of anti angiogenic agents such as bevacizumab within 4 weeks before surgical sampling.

  • 13. Previous allogeneic bone marrow transplantation or solid organ transplantation.

  • 14. Receipt of systemic anti tumor therapy within 4 weeks prior to lymphodepleting chemotherapy, except for the following:

    • Bridging therapy;
    • If prior chemotherapy with nitrosoureas or mitomycin C was administered, an interval of no less than 6 weeks between the end of such chemotherapy and the anticipated date of lymphodepleting chemotherapy is required for enrolment;
    • If prior small molecule targeted therapy was administered, an interval of no less than 5 half lives of the agent between the end of such therapy and the anticipated date of lymphodepleting chemotherapy is required for enrolment.
  • 15. Prior receipt of genetically modified or gene edited cell therapy products (excluding non genetically modified autologous immune cell therapy products administered more than 1 year before the date of cell infusion).

  • 16. History of hypersensitivity reaction to any component of investigational products to be used in the study, including but not limited to autologous TIL, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran 40, antibiotics (β-lactam antibiotics, gentamicin).

  • 17. Known psychiatric illness, alcoholism, drug addiction or substance abuse.

  • 18. Prior immune therapy related adverse events of Grade 3 or higher that have not recovered to CTCAE Grade 1 or less within 28 days; or any other disease or medical condition (any other illness, metabolic disorder, physical finding abnormality or laboratory abnormality) that would raise reasonable concerns prohibiting the use of investigational product, confound the interpretation of study results, or place the participant at high risk of treatment related complications.

  • 19. Pregnant or lactating women; or women with plans for pregnancy, conception or lactation within 1 year after the end of study treatment.

  • 20. Receipt of other investigational medicinal products within 4 weeks prior to lymphodepleting chemotherapy, or plan to receive other investigational medicinal products during the study.

  • 21. Other conditions deemed ineligible for enrollment at the investigator's discretion.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: GT201 treatment group

The treatment groups consist of monotherapy and combination therapy with PD-1. The monotherapy treatment is lymphodepleting chemotherapy followed by infusion of GT201 injection and IL-2. The combination therapy is lymphodepleting chemotherapy followed by infusion of GT201 injection and IL-2, along with continuous administration of PD-1 inhibitor therapy.

Infusion

Injection

Injection

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adverse events (AEs)
Periodo de tiempo: Up to 2 years

Incidence and severity of AEs, SAEs and AE leading to treatment interruption and discontinuation will be graded per NCICTCAE v5.0 (Phase 1)

Up to 2 years
Changes in laboratory parameters
Periodo de tiempo: Up to 2 years

Evaluate the safety and tolerability based on changes in laboratory parameters before and after treatment. (Phase 1)

Up to 2 years
Objective Response Rate (ORR)
Periodo de tiempo: Up to 2 years

Proportion of participants achieving a Complete Response (CR) or Partial Response (PR) per RECIST 1.1 (Phase 2).

Up to 2 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate (ORR)
Periodo de tiempo: Up to 2 years

Proportion of participants achieving a Complete Response (CR) or Partial Response (PR) per RECIST 1.1 (Phase 1).

Up to 2 years
Disease control rate (DCR)
Periodo de tiempo: Up to 2 years

Proportion of participants achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST 1.1 (Phase 1 and Phase 2).

Up to 2 years
Progression free survival (PFS)
Periodo de tiempo: Up to 2 years

The time from GT201 infusion to the first documentation of progressive disease (PD) per RECIST 1.1 or death from any cause, whichever occurs first (Phase 1 and Phase 2).

Up to 2 years
Duration of Response (DOR)
Periodo de tiempo: Up to 2 years

The duration from the first confirmed objective response per RECIST 1.1 to the first documentation of progressive disease (PD) or death from any cause (Phase 1 and Phase 2).

Up to 2 years
Overall survival (OS)
Periodo de tiempo: Up to 2 years

The time from GT201 infusion to death from any cause (Phase 1 and Phase 2).

Up to 2 years
CD3+ T cell counts
Periodo de tiempo: Up to 2 years

To evaluate the persistence and expansion of TILs in participants by measuring CD3+ T cell counts in peripheral blood following infusion of GT201 Injection (Phase 1 and Phase 2).

Up to 2 years
GT201 gene copy numbers
Periodo de tiempo: Up to 2 years

To evaluate the persistence and expansion of TILs in participants by measuring GT201 gene copy numbers in peripheral blood following infusion of GT201 Injection (Phase 1 and Phase 2).

Up to 2 years
Adverse events (AEs)
Periodo de tiempo: Up to 2 years

Incidence and severity of AEs, SAEs and AE leading to treatment interruption and discontinuation will be graded per NCICTCAE v5.0 (Phase 2)

Up to 2 years
Anti-drug antibodies (ADA)
Periodo de tiempo: Up to 2 years

Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (Nab) (Phase 1 and Phase 2).

Up to 2 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de noviembre de 2025

Finalización primaria (Estimado)

30 de diciembre de 2027

Finalización del estudio (Estimado)

30 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

20 de octubre de 2023

Primero enviado que cumplió con los criterios de control de calidad

17 de noviembre de 2023

Publicado por primera vez (Actual)

22 de noviembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir